The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relationship between quality of life (QoL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314.
M. Karthaus
Consultant or Advisory Role - Amgen
Honoraria - Amgen
J. Thaler
Honoraria - Amgen
Research Funding - Amgen
R. Hofheinz
Consultant or Advisory Role - Amgen; Merck; Roche; Sanofi
Honoraria - Amgen; Merck; Roche; Sanofi
Research Funding - Amgen; Merck; Roche
L. Mineur
Consultant or Advisory Role - Amgen
Honoraria - Amgen
H. Letocha
Consultant or Advisory Role - Amgen; Roche
R. Greil
No relevant relationships to disclose
E. Fernebro
No relevant relationships to disclose
E. Gamelin
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
A. BaƱos
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. Kohne
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Merck; Pfizer
Research Funding - Amgen; Merck; Pfizer; Roche